RESUMO
The complexity and inter-connectedness of operating in a global world for drug product supply has become an undeniable reality, further underscored by the COVID-19 pandemic. For Post-Approval Changes (PACs) that are an inevitable part of a product's commercial life, the impact of the growing global regulatory complexity and related drug shortages has brought the Global PAC Management System to an inflection point in particular for companies that have their products marketed in many countries.This paper illustrates through data analyzed for the first time from 145,000 + PACs for 156 countries, collected by 18 global pharma companies over a 3-year period (2019-2021), how severe the problem of global regulatory complexity is. Only PACs requiring national regulatory agency (NRA) approval prior to implementation were included in the data set. 1 of the 156 country NRAs approved all submitted PACs within a period of 6 months. The 6-month timeline was chosen because it is the recommended review timeline for major changes in the WHO guidance for vaccines and biotherapeutic products. 10 out of the 156 (6%) countries had no more than 10% of the PACs reviewed and approved in > 6 months. In 33 (22%) countries more than half of the PACs took > 6 months for approval. It is rare that the same PAC is approved globally within 6 months as individual NRAs take from a few months to years (in some cases > 5 years) for their review.The global PAC management complexity has steadily grown over the past 20 years. Attempts thus far to solve this problem have not made any meaningful difference. Senior leaders and decision-makers across the interdependent components of the complex Global PAC Management System (industry and regulators) must come together and collaboratively manage the problem holistically with the objective of ensuring global drug product availability instead of continuing with distinct stakeholder or country-focused solutions, which can tend to worsen the problem.In this paper, the Chief Quality Officers (CQOs) from 18 of the largest innovator pharma companies (see Acknowledgements) are speaking with One-Voice-of-Quality for PACs (1VQ for PACs Initiative). They are recommending a set of 8 approaches to activate a holistic transformation of the Global PAC Management System. This article presents their view on the problem of global regulatory complexity for managing PACs, it's impact on continual improvement and the risk to drug product supply, as well as approaches that can help alleviate the problem.
Assuntos
Aprovação de Drogas , Humanos , Aprovação de Drogas/organização & administração , COVID-19 , Indústria Farmacêutica/organização & administração , Indústria Farmacêutica/legislação & jurisprudência , Gestão de Mudança , Vigilância de Produtos Comercializados , SARS-CoV-2RESUMO
OBJETIVO: Descrever a organização das autoridades reguladoras nacionais (ARN) de medicamentos da Argentina, Brasil, Chile e Peru pela análise de categorias representativas de regras organizacionais. MÉTODOS: As ARN estudadas foram selecionadas utilizando-se os seguintes critérios: estar em país da América do Sul, ter sido identificada como ARN nos Encuentros de Autoridades Competentes en Medicamentos de los Países Iberoamericanos e apresentar boa disponibilidade de dados eletrônicos sobre estrutura e processo da regulação de medicamentos. Como principal fonte de dados, foram consultadas páginas eletrônicas entre maio de 2010 e março de 2011. As categorias analíticas foram: estrutura da organização, competências, direcionalidade e formas de responsabilidade e prestação de contas. RESULTADOS: As ARN da Argentina e do Brasil funcionavam como agências autônomas, enquanto que as do Chile e do Peru se subordinavam diretamente aos respectivos ministérios da saúde. À exceção da ARN brasileira, evidenciou-se a dependência das demais em relação ao ministério para emitir normas sanitárias. O escopo de ação de cada autoridade se diferenciou pelos bens e serviços a ela sujeitos, sendo a do Peru a única dedicada exclusivamente à regulação de medicamentos. As quatro ARN realizam todos os processos apontadas pela Organização Mundial da Saúde como essenciais para uma regulação efetiva. CONCLUSÕES: Os resultados apontam para um esforço dos países estudados em melhorar sua estrutura regulatória. Não obstante, em diversos aspectos, as quatro ARN ainda precisam aprimorar mecanismos para garantir, ao final da cadeia regulatória, a qualidade e a segurança dos medicamentos por elas regulados, com mais transparência nos processos decisórios e prestação de contas à sociedade.
OBJECTIVE: To describe the organization of national drug regulatory authorities (DRAs) in Argentina, Brazil, Chile, and Peru through the analysis of categories representing organizational rules. METHODS: The DRAs were selected using the following criteria: being in a South American country, having been identified as DRAs at Encuentros de Autoridades Competentes en Medicamentos de los Países Iberoamericanos (Conferences of Ibero-American Drug Regulatory Authorities), and having good availability of electronic data regarding organizational structure and the process of drug regulation. The main source of data were websites, which were reviewed between May 2010 and March 2011. The analytical categories were: organizational structure, competencies, directionality (mission and vision statements), and forms of accountability. RESULTS: The DRAs of Argentina and Brazil functioned as autonomous agencies, while those of Chile and Peru were directly subordinated to the ministries of health. Except for the Brazilian DRA, the agencies in the other three countries were dependent on their health ministries to issue sanitary regulations. The scope of action of each DRA differed in terms of the goods and services covered, with the Peruvian DRA being the only one exclusively dedicated to the regulation of drugs. The four DRAs performed all the processes identified by the World Health Organization as essential for effective drug regulation. CONCLUSIONS: The results show an effort by the studied countries to improve their regulatory structure. Nevertheless, all four DRAs need to improve some mechanisms to ensure that, at the end of the regulatory chain, the drugs they regulate have the desired quality and safety, with more transparency in decision-making processes and social accountability.